Inspire Medical Earnings Call: Growth Stalls Amid Reforms

Inspire Medical ((INSP)) has held its Q1 earnings call. Read on for the main highlights of the call.

Inspire Medical’s latest earnings call struck a cautious but steady tone, as modest revenue growth and improving margins were overshadowed by serious near‑term headwinds in coding, reimbursement, and a disruptive Medicare pilot. Management stressed its strong balance sheet and robust clinical data, but acknowledged that 2026 will likely be a down year as the business digests these shocks.

Revenue Growth Despite Operational Friction

In Q1 2026, revenue edged up 1.6% year over year to $204.6 million, reflecting continued adoption of Inspire’s sleep apnea therapy despite substantial administrative hurdles. Management emphasized that demand fundamentals remain intact, with growth driven by deeper market penetration rather than price or one‑off factors.

Margins and Profitability Metrics Still Improving

Profitability metrics moved in the right direction even as revenue growth slowed, with adjusted EBITDA margin expanding by 100 basis points to 17.5%. Adjusted operating income and operating cash flow improved versus last year, signaling that underlying cost discipline and efficiency initiatives are gaining traction.

Robust Cash Generation and Fortified Balance Sheet

Operating cash flow reached $12.8 million for the quarter, an improvement of roughly $20 million from the prior year period. With $400 million in cash and investments and no debt, Inspire underlined that it has ample financial flexibility to weather reimbursement turbulence and continue investing in growth.

Clinical Momentum Underpins Long-Term Thesis

Management highlighted a series of clinical and scientific milestones, including completion of the 5,000‑patient ADHERE trial and acceptance of the PREDICTOR manuscript for publication. Full Inspire V Singapore results and an independent VCU study showing significantly lower odds of major cardiovascular events in Inspire patients further strengthen the long‑term clinical value proposition, with more than 135,000 patients treated to date.

Field Force Optimization to Support Centers

The company ended the quarter with 284 U.S. territories and 288 field clinical reps, adding 13 reps in Q1 and achieving a one‑to‑one pairing with territory managers. Inspire is also consolidating territories in a targeted way, which management believes will create a more efficient and focused commercial organization, albeit with some near‑term disruption.

Product Flexibility Through Inspire IV Inventory

To help centers navigate reimbursement uncertainty around its latest system, Inspire has maintained inventory of the prior‑generation Inspire IV device. While the Q1 implant mix remained predominantly Inspire V, the availability of Inspire IV gives physicians and hospitals a bridge option where payers are hesitant, helping to sustain procedure volume.

Coding and Reimbursement Confusion Slows Pipeline

A central challenge is the fragmented coding environment for Inspire V, with Medicare contractors using a mix of codes while many commercial insurers rely on legacy or miscellaneous codes. This mismatch forces case‑by‑case manual reviews, slowing prior authorization processing and shrinking the near‑term procedure pipeline, despite underlying physician and patient interest.

WISER Pilot Weighs on Near-Term Volume

The WISER AI‑driven prior authorization pilot across six states has introduced additional delays for Medicare cases, compounding the coding issues. Inspire estimates that WISER reduced Q1 revenue by about $20 million and expects that impact to rise to $40–50 million in Q2, creating a meaningful temporary drag on growth.

Guidance Cut Reflects Material 2026 Revenue Headwind

Full‑year 2026 revenue guidance was reset to a range of $825–875 million, implying a 9–11% decline year over year once the combined $120–150 million hit from coding and WISER is considered. Management framed this as a largely timing‑driven headwind, but the cut underscores how administrative friction, rather than clinical or competitive failure, is reshaping the near‑term growth profile.

Profitability Compression and Q2 Loss Outlook

Diluted EPS came in at a loss of $0.39 in Q1, and Inspire now expects an adjusted operating loss of $10–15 million in Q2 as volumes remain constrained. For the full year, the company is guiding to a slim 2–4% adjusted operating margin, reflecting increased investment in reimbursement support and field resources amid revenue pressure.

Tax Volatility Adds Noise to Earnings

The reported effective tax rate spiked to 571.2% in Q1, driven by stock‑based compensation shortfalls amid share price swings. For 2026, management now anticipates a 65–70% effective tax rate, or 27–29% on an adjusted basis, meaning headline earnings may remain choppy even as underlying operations stabilize.

Market and Competitive Pressures Build at the Margins

Inspire also acknowledged emerging external headwinds, including increased use of GLP‑1 drugs and a competitor’s growing commercial presence, though the precise impact remains uncertain. Combined with coding confusion, these factors have dampened prior authorization submissions and pushed some procedures into later periods, further complicating near‑term forecasting.

Commercial Footprint Contraction and Transition

U.S. territories have contracted for three straight quarters and are down by the high‑teens percentage year over year as the company restructures its commercial model. While management argues that focused territory consolidation will ultimately enhance productivity and coverage, investors should expect ongoing short‑term noise in account relationships and case flow.

Guidance and Long-Term Outlook Amid Turbulence

Looking ahead, Inspire’s updated outlook calls for 2026 revenue of $825–875 million, a modest 2–4% adjusted operating margin, and adjusted diluted EPS of $0.75–1.25, with a Q2 adjusted operating loss of $10–15 million. Management is investing in education, reimbursement support, and inventory flexibility to ease disruption, and is targeting a long‑term coding solution in the form of a new procedure code expected to take effect in early 2028.

In summary, Inspire Medical’s earnings call painted a picture of a company with strong clinical credentials and a solid balance sheet navigating an unusually complex reimbursement storm. For investors, the near term may be volatile and pressured, but management’s message was that structural demand and long‑term growth drivers remain intact once administrative clouds clear.